• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Biotest AG - Product Pipeline Review - Q4 2010 Product Image

Biotest AG - Product Pipeline Review - Q4 2010

  • ID: 1446349
  • November 2010
  • 60 pages
  • GlobalData

Biotest AG – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “Biotest AG - Product Pipeline Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Biotest AG - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Biotest AG human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product READ MORE >



List of Tables
List of Figures
Biotest AG Snapshot
Biotest AG Overview
Key Information
Key Facts
Biotest AG – Research and Development Overview
Key Therapeutic Areas
Biotest AG – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Biotest AG – Pipeline Products Glance
Biotest AG Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Biotest AG–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Biotest AG – Drug Profiles
BT-061
Product Description
Mechanism of Action
R&D Progress
BT-062
Product Description
Mechanism of Action
R&D Progress
BT062
Product Description
Mechanism of Action
R&D Progress
BT-063
Product Description
Mechanism of Action
R&D Progress
BT-061
Product Description
Mechanism of Action
R&D Progress
Biotest AG – Pipeline Analysis
Biotest AG – Pipeline Products by Therapeutic Class
Biotest AG Pipeline Products By Target
Biotest AG – Pipeline Products by Route of Administration
Biotest AG – Pipeline Products by Molecule Type
Biotest AG – Recent Pipeline Updates
Biotest AG – Company Statement
Biotest AG – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Biotest AG - Key Manufacturing Facilities
Recent Developments
Nov 08, 2010: Biotest AG: Development of BT-062 Makes Further Progress With Start Of A New Clinical Trial
Dec 07, 2009: Immunoconjugate BT-062 Shows First Data Of Clinical Efficacy
Dec 07, 2009: Immunoconjugate BT-062 Shows First Data Of Clinical Efficacy
Oct 20, 2009: Biotest AG Announces, Monoclonal Antibody BT-061 Shows Efficacy In Patients With Rheumatoid Arthritis
Sep 30, 2009: Biotest AG Announces Initiation Of Clinical development Of BT-063
Sep 22, 2008: Promising Start Of Clinical Trial With BT062
Mar 11, 2008: Biotest Achieves Major Milestones In The Development Of Biotherapeutics
Dec 21, 2006: Biotest AG: Major milestones achieved in the development of monoclonal antibodies. – Commencement of clinical development of BT-061.
Dec 21, 2006: Biotest AG: Major milestones achieved in the development of monoclonal antibodies. – Commencement of clinical development of BT-061.
Jul 11, 2006: Biotest Secures Exclusive Rights To ImmunoGen’s World Leading Cytotoxic Agent Technology
Financial Deals Landscape
Biotest AG, Deals Volume Summary, 2004 to YTD 2010
Biotest AG, Deals Summary By Region, 2004 to YTD 2010
Biotest AG, Deals Summary, 2004 to YTD 2010
Biotest AG Detailed Deal Summary
Asset Purchase
Biotest Acquires Biologics Business Unit From Nabi Biopharmaceuticals
Acquisition
Bio-Rad Laboratories Completes Acquisition Of Medical Diagnostics Segment From Biotest
Biotest Sells Its 26% Stake In SIFIN
Equity Offering
Biotest Completes Private Placement Of $27.49 Million
Biotest Completes Private Placement Of $18.97 Million
Biotest Completes Private Placement Of $23.35 Million
Biotest Completes Private Placement Of $14.94 Million
Biotest Completes Private Placement Of $12.08 Million
Biotest Enters Into Research Collaboration With Johannes Gutenberg University
Biotest Enters Into Joint Venture With Sanquin
Biotest AG Enters Into Agreement With Boehringer Ingelheim
Biotest Signs Agreement With STRATEC
Licensing Agreements
ImmunoGen Enters Into Licensing Agreement With Biotest
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Note: Product cover images may vary from those shown

RELATED PRODUCTS